Bliss GVS Pharma: Promoter Group Sells 43.30% Stake for ₹1,369 Crore
Bliss GVS Pharma Limited announced that its promoter and public shareholders will sell 43.30% stake to Anupam Rasayan India Limited for ₹1,369.51 crore at ₹299 per share. This transaction triggers a mandatory open offer for up to 26% of equity. The Board noted the Share Purchase Agreement executed on May 23, 2026.
A change in control involving over 43% of the shareholding and a subsequent open offer for an additional 26% will significantly alter the company's ownership structure and potentially its strategic direction, thus having a high impact.
The announcement of a significant stake sale and potential change in control, coupled with a substantial transaction value and a clear open offer to public shareholders, is generally viewed positively as it indicates strategic activity and potential for future growth under new ownership.
Bliss GVS Pharma Limited announced that its Board of Directors has taken note of a Share Purchase Agreement (SPA) executed on May 23, 2026. Under this agreement, certain existing promoter and promoter group shareholders, along with public/non-promoter shareholders (collectively the "Sellers"), have agreed to sell a total of 4,58,03,024 equity shares, representing 43.30% of the company's paid-up equity share capital, to Anupam Rasayan India Limited (the "Purchaser").
The transaction involves the transfer of shares from sellers including Mr. Narsimha Shibroor Kamath (27.16%), Dr. Vibha Gagan Sharma (2.43%), Ms. Shruti Vishal Rao (1.99%), Mr. Gautam Rasiklal Ashra (1.94%), Mr. Arjun Gautam Ashra (4.25%), and M/s. Gulbarga Trading and Investment Private Limited (5.51%). The total consideration for this stake is ₹1,369.51 crore, with an agreed price of ₹299 per equity share.
The SPA also includes provisions for the Purchaser's option to acquire additional shares, termed "Balance Shares" and "Option Shares," under specific conditions and pricing. The acquisition of these shares, if exercised, will occur at ₹299 per equity share or at the prevailing market price, with a floor price of ₹299 for "Retained Shares" acquired off-market.
This transaction is expected to result in a change of shareholding and control of Bliss GVS Pharma Limited, subject to the fulfillment of conditions precedent and receipt of applicable statutory and regulatory approvals. The Purchaser's acquisition triggers a mandatory open offer to the public shareholders of the Company for up to 26% of the total paid-up equity share capital, in accordance with SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Following the open offer and full consummation of the SPA, the Purchaser will acquire control and be classified as a promoter of the Company. The Board meeting where this was noted commenced at 09:15 PM and concluded at 09:51 PM on May 23, 2026.
What to do with a filing like this
Bliss GVS Pharma Limited filed this with the NSE as a statutory disclosure, categorised under substantial acquisition of shares and takeovers. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Bliss GVS Pharma Limited. Read the original for the full detail.